Clinical Trials
153 trialsPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
STRASS2
European Organisation for Research and Treatment of Cancer - EORTC
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
National Cancer Institute (NCI)
SaLuDo
PharmaMar
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
TARSARC
Institut Bergonié
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
STORM Therapeutics LTD
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Polaris Group
ANTARES
Instituto do Cancer do Estado de São Paulo
A Study of Ivonescimab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
APROMISS
Advenchen Laboratories, LLC
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
PANTHR-S
Royal Marsden NHS Foundation Trust
REGOSTA
Centre Leon Berard
Localized Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
DAPPER
University Health Network, Toronto
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
PROSARC-1
Oslo University Hospital
PROSARC-2
Oslo University Hospital
POTENTIATE
Boundless Bio, Inc.
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
Northwestern University
TAIS
Fudan University
Metastatic Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
PEMBROSARC
Institut Bergonié
LEADER
National Taiwan University Hospital
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Memorial Sloan Kettering Cancer Center
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
ANNOUNCE
Eli Lilly and Company
SUNRISELMS
PTC Therapeutics
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
University of Utah
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
SAMHY2
Institut Claudius Regaud
CoRDS
Sanford Health
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
National Cancer Institute (NCI)
TAGGED
Sarcoma Oncology Research Center, LLC
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
ALCI2
Children's National Research Institute